Cargando…

High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome

BACKGROUND: Chromosome 4q loss of heterozygosity (LOH) is frequently observed in high-grade serous ovarian carcinoma (HGSOC). However, this LOH has not been clearly associated with the inactivation of any tumor suppressor gene(s). As the tumor suppressor gene PTPN13 is located on chromosome 4q21, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Hondt, Véronique, Lacroix-Triki, Magalie, Jarlier, Marta, Boissiere-Michot, Florence, Puech, Carole, Coopman, Peter, Katsaros, Dionyssios, Freiss, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707051/ https://www.ncbi.nlm.nih.gov/pubmed/29221157 http://dx.doi.org/10.18632/oncotarget.21175

Ejemplares similares

PTPN13 Participates in the Regulation of Epithelial–Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells
por: Aptecar, Leticia, et al.
Publicado: (2023)

Dual Role of the PTPN13 Tyrosine Phosphatase in Cancer
por: Mcheik, Soha, et al.
Publicado: (2020)

PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness
por: Hamyeh, Mohamed, et al.
Publicado: (2020)

The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex
por: Kassouf, Toufic, et al.
Publicado: (2019)

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2019)

Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures
por: Bobrie, Angelique, et al.
Publicado: (2022)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2014)

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
por: Baumbusch, Lars O., et al.
Publicado: (2013)

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
por: Fabbro, Michel, et al.
Publicado: (2020)

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival
por: Mansouri, Hanane, et al.
Publicado: (2020)

Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions
por: Buffard, Marion, et al.
Publicado: (2021)

PIK3R1(W624R) Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
por: D’Ambrosio, Concetta, et al.
Publicado: (2020)

High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma
por: Wang, Yu, et al.
Publicado: (2018)

Prognostic Value of CXCR2 in Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2020)

SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity
por: Alcaraz, Lindsay B., et al.
Publicado: (2022)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Netrin-1 overexpression is predictive of ovarian malignancies
por: Papanastasiou, Anastasios D., et al.
Publicado: (2011)

Concomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses
por: Ventura, Pedro M O, et al.
Publicado: (2022)

Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms
por: Jones, Paul Michael, et al.
Publicado: (2013)

Body Composition and Metabolic Dysfunction Really Matter for the Achievement of Better Outcomes in High-Grade Serous Ovarian Cancer
por: Cuello, Mauricio A., et al.
Publicado: (2023)

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study
por: Fabbro, Michel, et al.
Publicado: (2022)

Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
por: Bibeau, F, et al.
Publicado: (2013)

High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation
por: White, Elizabeth A., et al.
Publicado: (2016)

High-expressed PTPN1 promotes tumor proliferation signature in human hepatocellular carcinoma
por: Xie, Liping, et al.
Publicado: (2023)

Redoxing PTPN22 activity
por: Shumanska, Magdalena, et al.
Publicado: (2022)

Curcumin inhibits proliferation of hepatocellular carcinoma cells by blocking PTPN1 and PTPN11 expression
por: Zhang, Jingru, et al.
Publicado: (2023)

Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells
por: Cherradi, Sara, et al.
Publicado: (2023)

Catalytically inactive human cathepsin D triggers fibroblast invasive growth
por: Laurent-Matha, Valérie, et al.
Publicado: (2005)

Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells
por: Naldi, Aurélien, et al.
Publicado: (2017)

PTPN22.6, a Dominant Negative Isoform of PTPN22 and Potential Biomarker of Rheumatoid Arthritis
por: Chang, Hui-Hsin, et al.
Publicado: (2012)

Genetic Variations of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease
por: Sharp, Robert C., et al.
Publicado: (2015)

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
por: Baumgartner, Christina K., et al.
Publicado: (2023)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
por: Bobrie, Angélique, et al.
Publicado: (2022)

Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer
por: YING, LISHA, et al.
Publicado: (2013)

Genetic variation in PTPN1 contributes to metabolic adaptation to high-altitude hypoxia in Tibetan migratory locusts
por: Ding, Ding, et al.
Publicado: (2018)

Oncogenes in high grade serous adenocarcinoma of the ovary
por: Manasa, Pacharla, et al.
Publicado: (2020)

Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein
por: Genera, Mariano, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tjead32mcapbbmmmbsluljt6gk